Integer Holdings Corp

Joseph Dziedzic, as CEO, holds ultimate responsibility for capital allocation, which is executed primarily through acquisitions of complementary component manufacturers. The board of directors, chaired by Bill Bozsan, oversees major strategic transactions. Day-to-day merger-and-acquisition sourcing is managed by the corporate development function, which reports through the CFO.

Integer targets privately held companies that manufacture proprietary components within its existing cardiac, neuromodulation, or vascular segments. The firm's deep integration with medtech OEMs gives it visibility into supplier gaps years in advance. Engineering teams at Integer sites often identify technologies that, if acquired, could shorten a customer's product-development cycle, which then informs the corporate development mandate.

Integer is a pure outsourcer and does not sell any finished medical devices under its own brand. Its entire business model depends on being a trusted, conflict-free partner to the large OEMs that set the device specifications. The company actively avoids taking clinical or regulatory ownership of end products, which keeps it from competing with Abbott, Medtronic, or Boston Scientific.

Integer's non-medical segment — primarily batteries and power systems for military and aerospace uses — accounts for less than 5 percent of total revenue. It originated from Greatbatch's historical work on lithium-iodide batteries for implantable pacemakers, where similar power-management chemistry has dual-use applications. The segment provides some technical commonality but minimal strategic crossover with the core medical-manufacturing business.

Integer's moat rests on a combination of regulatory-entrenched supplier qualification, proprietary component intellectual property, and co-located engineering teams. For active implantables, a new supplier requires years of FDA supplemental approvals just to change a single material source, making OEMs reluctant to switch. The firm's on-site innovation centers in medtech hubs like Minnesota embed Integer engineers directly into customer design cycles, creating structural stickiness that price competition alone cannot break.

Integer does not compete in commoditized medical disposables like syringes, tubing sets, or surgical drapes — segments where low barriers to entry compress margins. It also avoids diagnostics and consumer health devices, concentrating exclusively on the regulated, high-barrier active-implantable and vascular-access markets where its cleanroom and battery-chemistry infrastructure provides durable insulation from generic contract manufacturers.

Integer operates roughly 26 sites, with major clusters in Plymouth and Brooklyn Park, Minnesota; Alden, New York; Beaverton, Oregon; Tijuana, Mexico; Montevideo, Uruguay; and Galway, Ireland. The Minnesota footprint is particularly significant because it situates the company's engineering teams adjacent to the Twin Cities metro, the densest medtech cluster in the world.